news
12 December 2016

PTC Therapeutics Receives France’s 2016 Prix Galien for Translarna™

Share

Award recognizes scientific innovation of first approved drug for underlying cause of nonsense mutation Duchenne muscular dystrophy

The award in the Medicines “Rare Disease” category recognizes the scientific innovation represented by Translarna’s ability to target the underlying cause of nonsense mutation Duchenne muscular dystrophy (nmDMD) and the impact the drug is having on nmDMD patients and their families.

Please click here for a full reading http://ir.ptcbio.com/releasedetail.cfm?ReleaseID=1003370

 

 

Latest News